Natalizumab for the treatment of relapsing multiple sclerosis

Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an &alpha;4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard A Rudick, Michael A Panzara
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4b8f45d87cdf40a88c04b2ca437e248d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b8f45d87cdf40a88c04b2ca437e248d
record_format	dspace
spelling	oai:doaj.org-article:4b8f45d87cdf40a88c04b2ca437e248d2021-12-02T04:18:39ZNatalizumab for the treatment of relapsing multiple sclerosis1177-54751177-5491https://doaj.org/article/4b8f45d87cdf40a88c04b2ca437e248d2008-06-01T00:00:00Zhttp://www.dovepress.com/natalizumab-for-the-treatment-of-relapsing-multiple-sclerosis-a1725https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an &alpha;4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in the pivotal AFFIRM study (N = 942). Natalizumab monotherapy reduced risk of disability progression by 42%&ndash;54% and annualized relapse rate by 68% during a period of 2 years. Natalizumab was also associated with significant reductions in number of T2-hyperintense, gadolinium-enhancing, and T1-hypointense lesions and in volume of T2-hyperintense lesions (all p &lt; 0.001) on magnetic resonance imaging. Furthermore, natalizumab-treated patients in AFFIRM experienced significant improvements from baseline in the physical and mental components of the Short Form-36 (p &le;&nbsp;0.01) and a 35% reduction in risk of clinically significant vision loss (p = 0.008 vs placebo). Natalizumab was well tolerated in phase 3 studies. Common adverse events were generally mild and included headache, fatigue, urinary tract infections, and arthralgia. Serious adverse events were similar between treatment groups. The incidence of serious hypersensitivity reactions associated with natalizumab was &lt;1%. Progressive multifocal leukoencephalopathy was a rare complication of treatment, observed in 2 patients with MS who received natalizumab plus interferon &beta;-1a. The robust clinical benefits of natalizumab, including benefits on patient-reported quality of life, make it an important addition to disease-modifying therapies available to patients with relapsing MS.Keywords: multiple sclerosis, natalizumab, &alpha;4-integrin antagonist Richard A RudickMichael A PanzaraDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 189-199 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Richard A Rudick Michael A Panzara Natalizumab for the treatment of relapsing multiple sclerosis
description	Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an &alpha;4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in the pivotal AFFIRM study (N = 942). Natalizumab monotherapy reduced risk of disability progression by 42%&ndash;54% and annualized relapse rate by 68% during a period of 2 years. Natalizumab was also associated with significant reductions in number of T2-hyperintense, gadolinium-enhancing, and T1-hypointense lesions and in volume of T2-hyperintense lesions (all p &lt; 0.001) on magnetic resonance imaging. Furthermore, natalizumab-treated patients in AFFIRM experienced significant improvements from baseline in the physical and mental components of the Short Form-36 (p &le;&nbsp;0.01) and a 35% reduction in risk of clinically significant vision loss (p = 0.008 vs placebo). Natalizumab was well tolerated in phase 3 studies. Common adverse events were generally mild and included headache, fatigue, urinary tract infections, and arthralgia. Serious adverse events were similar between treatment groups. The incidence of serious hypersensitivity reactions associated with natalizumab was &lt;1%. Progressive multifocal leukoencephalopathy was a rare complication of treatment, observed in 2 patients with MS who received natalizumab plus interferon &beta;-1a. The robust clinical benefits of natalizumab, including benefits on patient-reported quality of life, make it an important addition to disease-modifying therapies available to patients with relapsing MS.Keywords: multiple sclerosis, natalizumab, &alpha;4-integrin antagonist
format	article
author	Richard A Rudick Michael A Panzara
author_facet	Richard A Rudick Michael A Panzara
author_sort	Richard A Rudick
title	Natalizumab for the treatment of relapsing multiple sclerosis
title_short	Natalizumab for the treatment of relapsing multiple sclerosis
title_full	Natalizumab for the treatment of relapsing multiple sclerosis
title_fullStr	Natalizumab for the treatment of relapsing multiple sclerosis
title_full_unstemmed	Natalizumab for the treatment of relapsing multiple sclerosis
title_sort	natalizumab for the treatment of relapsing multiple sclerosis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/4b8f45d87cdf40a88c04b2ca437e248d
work_keys_str_mv	AT richardarudick natalizumabforthetreatmentofrelapsingmultiplesclerosis AT michaelapanzara natalizumabforthetreatmentofrelapsingmultiplesclerosis
_version_	1718401309022879744

Natalizumab for the treatment of relapsing multiple sclerosis

Ejemplares similares